GENOSCIENCE PHARMA
π«π·France
- Country
- π«π·France
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
Phase 1
- Conditions
- Primary Liver Cancer
- Interventions
- Drug: GNS561 oral tablets and capsules
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Genoscience Pharma
- Target Recruit Count
- 27
- Registration Number
- NCT05353894
- Locations
- π«π·
Genoscience Pharma, Marseille, France
A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Genoscience Pharma
- Target Recruit Count
- 178
- Registration Number
- NCT04637828
- Locations
- π«π·
Genoscience Pharma, Marseille, France
Study of GNS561 in Patients With Liver Cancer
Phase 1
Terminated
- Conditions
- Hepatocellular CarcinomaCholangiocarcinoma, Intrahepatic
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Genoscience Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT03316222
- Locations
- π«π·
Saint-Joseph Hospital, Paris, France
π«π·CHU Grenoble, Grenoble, France
π§πͺJules Bordet Institute, Brussel, Belgium
Β© Copyright 2025. All Rights Reserved by MedPath